

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/789,821
		Filing Date	February 27, 2004
		First Named Inventor	Lifshitz-Liron, et al.
		Art Unit	1625
		Examiner Name	Unassigned
Sheet 2 of 2	Attorney Docket Number	01662/62902	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/R.D./		"Zoledronate Disodium", Drugs of the Future, 2000, 25(3): 259-268	
/R.D./		KIECZYKOWSKI et al., 1995, "Preparation of (4-amino-1-hydroxybutylidene)bisphosphonic acid sodium salt, MK-217 (alendronate sodium). An improved procedure for the preparation of 1-hydroxy-1,1-bisphosphonic acids", J. Org. Chem. 60:8310-8312.	
/R.D./		MULLER et al., "Effects of the Bisphosphonate Zolendronate on Bone Loss in the Ovariectomized and in the Adjuvant Arthritic Rat", Arzneimittelforschung, vol. 48, no. 1, 1998, pages 81-86	
/R.D./		WIDLER et al., 2002, "Highly potent geminal bisphosphonates. from pamidronate disodium (Aredia) to zoledronic acid (Zometa)", J. Med. Chem. 45:3721-3738.	
/R.D./		ZHAO et al., 2002, "FDA new drug approvals in 2001", Drug Development 3:400-413.	
/R.D./		ZHU et al., 2003, "Synthesis of zoledronic acid", Chinese J. New Drugs 12:39-40.	✓

Examiner Signature	/Rita Desai/	Date Considered	06/14/2007
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.